Endobronchial Ultrasound Biopsy Market By Product Type (Convex Probe Endobronchial Ultrasound (CP-EBUS), Radial Probe Endobronchial Ultrasound (RP-EBUS), EBUS-Guided Transbronchial Needles, Accessories), By Application (Lung Cancer Diagnosis and Staging, Pulmonary Infections Diagnosis, Inflammatory and Infectious Diseases, Others), By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Diagnostic Centers, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape the Endobronchial Ultrasound Biopsy Market in the coming years?

The Endobronchial Ultrasound Biopsy Market accounted for USD 681.20 Million in 2024 and USD 732.56 Million in 2025 is expected to reach USD 1515.46 Million by 2035, growing at a CAGR of around 7.54% between 2025 and 2035. The Endobronchial Ultrasound Biopsy market represents a subset of the medical devices and procedures market, focusing on the study of diagnostic instruments for the lower respiratory system, specifically for lung diseases, including lung cancer, as well as infections and abnormalities in the mediastinum. BUS integrates bronchoscopy with real-time ultrasound imaging, which allows the doctor to see the air as well as tissues around it, not to mention lymph nodes. Such technology enables the sampling of the tissue by the use of fine needle aspiration without any surgical processes, such as mediastinoscopy, thus decreasing the patient's risk and recovery period.

The market has become significant with an increasingly prevalent lung cancer and respiratory-related diseases across the globe, as well as the growing need among consumers to access reliable early-stage lung cancer diagnostics. Hospitals, diagnostic, and specialty clinics are the primary end-users of EBUS biopsy systems who are interested in enhancing clinical outcomes due to early disease detection. The development of imaging technologies and an increase in preference for minimally invasive procedures are other factors contributing to market growth. In addition, lung cancer provision of awareness about screening of cancer and governmental support for the advanced technologies of diagnostic tools have facilitated its adoption both in developed and developing regions.  

What do industry experts say about the Endobronchial Ultrasound Biopsy Market trends?

"Endobronchial ultrasound (EBUS) has revolutionized the diagnosis and staging of lung cancer, offering a minimally invasive approach with high diagnostic yield."

• Dr. Neal Navani, Consultant Respiratory Physician, University College London Hospitals NHS Foundation Trust

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Endobronchial Ultrasound Biopsy Market?

How is the rising global prevalence of lung cancer fueling demand for EBUS biopsy procedures?

Increasing global lung cancer incidence is one of the major contributing factors in the Endobronchial Ultrasound (EBUS) Biopsy Market. Lung cancer is the most frequent cancer-causing mortality, with numbers coming to stage length of approximately 2.5 million in 2022. The urgency of early and accurate diagnostic techniques can be seen in this spike. CP-EBUS in particular has become a key standard in mediastinal staging because of its capacity to offer real-time imaging and drawing of minimally invasive tissue samples. Its use in clinical practice allows correct diagnosis and staging, which is important in the process of planning an effective treatment.

The growing popularity of lung cancer, the benefits of EBUS in early diagnosis and precision medicine, also play a key role in demanding its implementation in healthcare facilities worldwide. The trend is backed by the fact that the American Cancer Society estimates 226,650 new cases of lung cancer in 2025 in the United States, which indicates a steadily increasing burden of the disease. This figure depicts a larger trend in the world wherein the use of advanced diagnostic tools such as EBUS is essential to ensure cancerous growths in the lung are addressed, which underpins market growth.

Why are healthcare providers increasingly shifting toward minimally invasive diagnostics instead of surgical biopsies?

The endobronchial ultrasound (EBUS) biopsy is gaining popularity among health care providers, as compared to surgical biopsy, by reducing invasive procedures because of various factors that are about to increase the EBUS biopsy market. The processes present less pain to the patient, less recovery time, and fewer issues than the open surgical procedures. In comparison, less-painful biopsies with low invasiveness are related to early recovery of the daily routine, the satisfaction of the patient, and patient compliance is higher.

Further, these methods can be conducted on an outpatient basis, thus saving hospitalization and expenses incurred. According to the American College of Surgeons, the reduction in patient suffering associated with minimally invasive surgery is not the only positive factor it will bring: it will also make the process of healthcare delivery more efficient. This created a rising tendency of using these techniques in a clinical practice, which is evoked by a shift toward patient-oriented care and solution-oriented healthcare, effective solutions that positively influence the EBUS Biopsy Market growth.

How do high equipment acquisition and maintenance costs limit EBUS adoption in smaller healthcare facilities?

Expensive tools and equipment maintenance costs are another major limitation posed by the Endobronchial Ultrasound Biopsy Market, especially in smaller centers and clinics. Such medical equipment as BUS systems, such as bronchoscopes and ultrasound processors, and specialized needles, are costly to purchase and may be out of the budget of mid-tier hospitals or diagnostic centers with a limited budget. Besides the initial cost, costs of maintenance, calibration, and replacement of disposable parts will be incurred in the course of operation.

Smaller facilities will also have a hard time justifying the cost if the number of patients is low and the ROI is low. Such an economic roadblock limits large-scale integration of the EBUS technology among the developing parts of the world and in rural locations. One result is that high prices may slow the upgrading of diagnostic infrastructure and encourage healthcare providers to use traditional or lower-priced diagnostic techniques. All in all, even though EBUS has clinical potential, it is cost-prohibitive, which is one of the primary issues that has a negative impact on the market expansion.

How are rising investments in healthcare infrastructure across emerging economies opening new growth avenues for EBUS adoption?

The increasing investments in healthcare infrastructure in the emerging economies provide a massive potential for the Endobronchial Ultrasound Biopsy Market. There is a growing number of hospitals, cancer centers, and diagnostic facilities being built by governments and the private sector, and therefore, there is a growing need for advanced diagnostics, such as EBUS. Physicians with improved infrastructure can use more minimally invasive procedures and fewer traditional surgical biopsies. Besides, the investments in training processes and technological improvements and advances in the capacity of local medical professionals to conduct EBUS-guided processes efficiently.

Other countries, including India, China, and Brazil, are now putting more emphasis on checks on early cancer detection, and that is another factor towards the rising demand for accurate tissue sampling. The possibility of expanding insurance coverage and government-supported healthcare programs also increases access to such procedures by the patient population. Taken together, these trends present novel growth opportunities in the uptake of EBUS, which in turn can facilitate market expansion into areas that have remained underserved.

How can AI and machine learning integration enhance real-time imaging and diagnostic support in EBUS procedures?

The area of opportunity by integrating AI and machine learning into Endobronchial Ultrasound Biopsy Market procedures is to improve real-time imaging and diagnostic assistance. AI algorithms have the potential to aid clinicians in detecting precise lymph nodes, lesions, and tissue abnormalities detection and can make the process less operator-dependent and less prone to human error. Machine learning models have the potential to process ultrasound images to provide predictive insights, precision in needle-placing, and sample optimization in a procedure.

This technology also allows results to be interpreted in a shorter period of time, facilitating more timely treatment decisions and personalized care to patients. As well, AI-enhanced platforms can also be used to train new pulmonologists, practicing complex situations and giving performance results. Integration of such intelligent systems will enhance the efficiency of the procedure, enhance the diagnostic yield, and strengthen clinical confidence. Hospitals and diagnostic centers are extensively embracing digital and AI-based technology, and this aspect is likely to fuel the adoption of EBUS systems on a global scale, presenting the EBUS Biopsy Market with an opportunity to expand rapidly.

What are the key market segments in the Endobronchial Ultrasound Biopsy industry?

Based on the product type, the Market of Endobronchial Ultrasound Biopsy has been classified into Convex Probe Endobronchial Ultrasound (CP-EBUS), Radial Probe Endobronchial Ultrasound (RP-EBUS), EBUS-guided transbronchial Needle, and Accessories. Convex Probe Endobronchial Ultrasound (CP-EBUS) is the most dominant product type in the Endobronchial Ultrasound (EBUS) Biopsy market. The main reason why CP-EBUS is widely preferred is that it allows real-time imaging of the mediastinal and hilar lymph nodes and leads to their guided transbronchial needle aspiration, which makes it highly efficient in lung cancer diagnosis and staging. The fact that it could yield ultrasound visualization as well as deliver tissue sampling through the same procedure has made it the standard of minimally invasive diagnosis.

Hospitals and other cancer centers are actively introducing CP-EBUS because it eliminates the need to perform invasive surgical interventions such as mediastinoscopy, therefore, lowering the risks for patients and the terms of their recovery. Its dominance is further improved by a high degree of diagnostic yield, accuracy in the staging of lung cancer, and facilitation of the processing of biomarker testing. Also, foreign oncology standards state that CP-EBUS should be adopted as the initial method of mediastinal examination, stimulating its adoption further.

Based on the Applications, the Market of Endobronchial Ultrasound Biopsy has been classified into Lung Cancer Diagnosis and Staging, Pulmonary infection diagnosis, Inflammatory and Infectious Diseases, and Others. Lung Cancer Diagnosis and Staging is the most powerful application segment of the Endobronchial Ultrasound (EBUS) Biopsy market. Lung cancer is considered one of the most common causes in terms of cancer-related deaths worldwide, igniting a high demand for accurate and minimally invasive diagnostic modalities. This is because BUS, especially when it is used in conjunction with transbronchial needle aspiration, can accurately biopsy mediastinal and hilar lymph nodes that are important to the staging and treatment planning.

It excels over traditional diagnostic methods because it accomplishes enhanced imaging and tissue acquisition in real-time in one process. EBUS is now a standard of care in lung cancer staging in clinical guidelines in major regions, and this also increases its uptake. The emerging prevalence of non-small cell lung cancer (NSCLC) and the increasingly relevant role of biomarker testing as a means of prescribing targeted therapy compounds also underline the necessity of EBUS-based tissue sampling. Cancer centers, specialized clinics, and hospitals use EBUS extensively for early detection and the making of a personalized decision towards treatment.

Which regions are leading the Endobronchial Ultrasound Biopsy Market, and why?

The North America Endobronchial Ultrasound Biopsy Market has already seen healthy uptake due to the high rate of lung cancer, well-established hospital infrastructure, and popularity of minimally invasive diagnosis techniques. Uptake in the U.S. can be attributed to established reimbursement mechanisms, the development of thoracic oncology guidelines recommending needle sampling of mediastinal nodes, and the high concentrations of NCI-designated and academic centers, which serve to standardize the use of EBUS in staging pathways. These trends are reflected in Canada through both provincially-based cancer programs and centralized procurement, which facilitate diffusion into teaching hospitals and regional centers.

The demand is backed up by lung cancer screening cohort expansion, driving earlier, tissue-sparing diagnosis and testing, repeat sampling, and biomarkers. In terms of clinical use, integration with navigation bronchoscopy and real-time cytology is increasing utilization in small or more complicated target areas. Operationally, for community locations, both the costs of capital as well as the training curve remain the impediments; however, referral networks and paradigm of mobile service are some of the ways to extend access. Procedurally, more of these will be done in an outpatient setting with streamlined sedation continuums, which enhance economics and throughput.

In the Asia Pacific Endobronchial Ultrasound Biopsy market, the presence of increasing cases of lung cancer and the subsequent augmented use of minimally invasive methodologies of diagnosis are the key trends fuelling the expansion of the market. China and India, in particular, have experienced growth driven by a high population of patients, urbanisation-related prevalence of respiratory diseases, and an expanding healthcare infrastructure. Japan also takes the lead in the integration of technology, where high-tech hospitals have embraced the use of EBUS in the mainstream of cancer staging due to powerful government health measures. Australia and South Korea also present a very important usage, especially in specialised oncology and respiratory hospitals.

This is becoming more accessible since more pulmonologists are taking the training and awareness campaigns to embrace the use of EBUS-guided procedures. Nonetheless, the low cost of equipment and rather non-uniform provision of advanced healthcare infrastructure in rural regions are the undesirable aspects. The emphasis by the Government on cancer detection at an early stage and the amount of money invested in diagnostic imaging technologies are aiding penetration in the market.

What does the competitive landscape of the Endobronchial Ultrasound Biopsy Market look like?

The Endobronchial Ultrasound Biopsy market is highly competitive due to the presence of a variety of major globally established manufacturers of medical supplies and the existence of specialized smaller manufacturers that specialize in bronchoscopy and minimally invasive diagnostics. Market leaders like Olympus, Fujifilm, and Medtronic have powerful lines of bronchoscopes, ultrasound processors, and needle systems with broad markets and distribution channels and high R&D competencies. Boston Scientific, Cook Medical, and CONMED complement competition with diversified interventional pulmonology solutions, whereas Pentax Medical and Karl Storz are based on imaging reliability and equipment innovation.

New entrants such as Broncus Medical, Ambu, and Micro-Tech Endoscopy are gaining momentum with their innovative biopsy accessories at an affordable cost, with technological advancements to meet the increasing needs of the East Asian and developing countries. Strategic partnerships with hospitals, the pulmonologist-training initiatives, and a combination of EBUS and navigation bronchoscopy contribute to intensifying competition. The other aspects that companies compete on are aspects like clear image, durability of the needles, convenience of use, and after-sales services to gain market share.  

Endobronchial Ultrasound Biopsy Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Endobronchial Ultrasound Biopsy industry?

• In August 2024, Upstate Medical University introduced a minimally invasive robotic-assisted lung biopsy, enhancing precision and safety. This advanced procedure enables earlier detection of lung cancers, improving patient outcomes and reducing recovery time.

Report Coverage:

By Product Type

• Convex Probe Endobronchial Ultrasound (CP-EBUS)
• Radial Probe Endobronchial Ultrasound (RP-EBUS)
• EBUS-Guided Transbronchial Needles
• Accessories

By Application

• Lung Cancer Diagnosis and Staging
• Pulmonary Infections Diagnosis
• Inflammatory and Infectious Diseases
• Others

By End-User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Diagnostic Centers
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Olympus Corporation
• Fujifilm Holdings Corporation
• Medtronic plc
• Cook Medical
• Boston Scientific Corporation
• CONMED Corporation
• Pentax Medical
• Karl Storz SE & Co. KG
• Richard Wolf GmbH
• Medi-Globe GmbH
• Veran Medical Technologies
• Ambu A/S
• SonoScape Medical Corp.
• Broncus Medical Inc.
• Micro-Tech Endoscopy

Frequently Asked Questions (FAQs)